James Mackaness - Dec 11, 2023 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Chief Financial Officer
Signature
/s/ James Mackaness
Stock symbol
SLNO
Transactions as of
Dec 11, 2023
Transactions value $
-$1,143,903
Form type
4
Date filed
12/13/2023, 09:34 PM
Previous filing
Dec 4, 2023
Next filing
Jan 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Options Exercise $38.9K +15K +50.66% $2.60* 44.6K Dec 11, 2023 Direct F1
transaction SLNO Common Stock Sale -$222K -6.25K -14.01% $35.49 38.4K Dec 11, 2023 Direct F2
transaction SLNO Common Stock Sale -$448K -12.4K -32.28% $36.16 26K Dec 11, 2023 Direct F3
transaction SLNO Common Stock Sale -$513K -13.8K -53.31% $37.06 12.1K Dec 11, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Options Exercise $0 -15K -75% $0.00 5K Dec 11, 2023 Common Stock 15K $2.60 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The 1-for-15 reverse stock split of the Issuer's Common Stock, effected August 26, 2022, was reflected in a Form 4 filed by the Reporting Person on October 14, 2023. The number of shares reported as beneficially owned following the reported transaction has been reduced by two shares to reflect share rounding as a result of such stock split.
F2 This transaction was executed in multiple trades at prices ranging from $34.83 to $35.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $35.83 to $36.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $36.84 to $37.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The option, originally for 20,000 shares, vested as to one fourth of the shares on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.